BIO-TECHNE Corp (TECH) — SEC Financial Statements & Analysis

BIO-TECHNE Corp (TECH) is a biological products, (no diagnostic substances) company, incorporated in MN. BIO-TECHNE Corp trades on Nasdaq as: TECH. BIO-TECHNE Corp (TECH)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-08-24. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), BIO-TECHNE Corp carries a market cap of $11.01B, a P/E ratio of 60.52x, a P/B ratio of 5.22x, a P/S ratio of 9.06x, an enterprise value of $10.94B, and an EV/EBITDA multiple of 31.33x. On profitability, it posts a gross margin of 65.77%, an operating margin of 20.73%, a net margin of 14.97%, a Return on Equity (ROE) of 9.03%, a Return on Assets (ROA) of 7.07%, and a Return on Invested Capital (ROIC) of 9.07%. Per share, it reports EPS of $1.17, diluted EPS of $1.16, free cash flow per share of $1.69, and a dividend per share of $0.32. Over the trailing year, it posted revenue growth of -0.38% year-over-year, net income growth of 147.77% year-over-year, and EPS growth of 150.24% year-over-year. On the balance sheet, it maintains a current ratio of 4.55x, a quick ratio of 3.35x, working capital of $580.70M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.06, free cash flow of $263.22M (TTM), and net debt of $-64.71M. Figures sourced from SEC EDGAR.

Market Cap

$11.01B

P/E TTM

60.52x

EPS TTM

$1.17

P/B TTM

5.22x

ROE TTM

9.03%

ROA TTM

7.07%

Debt To Equity

0.08x

Free Cash Flow TTM

$263.22M

Net Revenue TTM Growth 1Y

-0.38%

Data as of 2026-06-30 · Source: SEC EDGAR